Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1

Resistance to androgen deprivation therapy, or castration-resistant prostate cancer (CRPC), is often accompanied by metastasis and is currently the ultimate cause of prostate cancer-associated deaths in men. Recently, secondary hormonal therapies have led to an increase of neuroendocrine prostate ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, En-Chi, Rice, Meghan A., Bermudez, Abel, Marques, Fernando Jose Garcia, Aslan, Merve, Liu, Shiqin, Ghoochani, Ali, Zhang, Chiyuan Amy, Chen, Yun-Sheng, Zlitni, Aimen, Kumar, Sahil, Nolley, Rosalie, Habte, Frezghi, Shen, Michelle, Koul, Kashyap, Peehl, Donna M., Zoubeidi, Amina, Gambhir, Sanjiv S., Kunder, Christian A., Pitteri, Sharon J., Brooks, James D., Stoyanova, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2020
Materias:
PNAS Plus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994991/
https://www.ncbi.nlm.nih.gov/pubmed/31932422
http://dx.doi.org/10.1073/pnas.1905384117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994991/
https://www.ncbi.nlm.nih.gov/pubmed/31932422
http://dx.doi.org/10.1073/pnas.1905384117

Ejemplares similares